Narcotic Antagonists

"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents inhibiting the effect of narcotics on the central nervous system.

Descriptor ID	D009292
MeSH Number(s)	D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
Concept/Terms	Narcotic Antagonists Narcotic Antagonists Antagonists, Narcotic Opioid Receptor Antagonists Antagonists, Opioid Receptor Receptor Antagonists, Opioid Opioid Antagonists Antagonists, Opioid Competitive Opioid Antagonists Competitive Opioid Antagonists Antagonists, Competitive Opioid Opioid Antagonists, Competitive

Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Narcotic Antagonists [D27.505.696.543]
Peripheral Nervous System Agents [D27.505.696.663]
Sensory System Agents [D27.505.696.663.850]
Narcotic Antagonists [D27.505.696.663.850.512]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Narcotic Antagonists [D27.505.954.427.550]

Below are MeSH descriptors whose meaning is related to "Narcotic Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.

Bar chart showing 98 publications over 21 distinct years, with a maximum of 13 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2004	0	1	1
2007	0	2	2
2008	5	1	6
2009	1	1	2
2010	1	1	2
2011	2	1	3
2012	4	1	5
2013	3	3	6
2014	5	1	6
2015	3	1	4
2016	2	1	3
2017	11	2	13
2018	6	1	7
2019	4	0	4
2020	2	4	6
2021	0	4	4
2022	0	5	5
2023	0	3	3
2024	3	5	8
2025	4	3	7

Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.

Ostrowski SJ, Adkins A, Goldfarb D, Kukowski M, Stratton D, Barton DJ, Pizon AF. Transdermal buprenorphine patch-facilitated induction of sublingual buprenorphine in hospitalized patients receiving full agonist opioids: a retrospective cohort study. Clin Toxicol (Phila). 2025 Nov; 63(11):897-905.

View in: PubMed
Friedmann PD, Wilson D, Stopka TJ, Bernson D, Pivovarova E, Ferguson W, Hoskinson RA, Rottapel RE, Bovell-Ammon B, Gaba A, Morgan JR, Senst T, Hayes E, Evans EA. Medications for Opioid Use Disorder in County Jails - Outcomes after Release. N Engl J Med. 2025 Sep 11; 393(10):994-1003.

View in: PubMed
Ober AJ, Murray-Krezan C, Page K, Friedmann PD, Anderson J, Osilla KC, Ryzewicz S, Huerta S, Mazer MW, Hoskinson RA, Garvey R, Peltz A, Watkins KE, Nuckols T, IsHak WW, Mariano LT, Danovitch I. Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial. JAMA Intern Med. 2025 Jun 01; 185(6):624-633.

View in: PubMed
Broach JP, Rettger B, Gigliotti R, Chapman BP, Joseph J, Smiley A, Hunter M, Soucie N, Gross K, Babu KM, Weisberg SN. Creating Opioid Response Specialists: A Harm Reduction Initiative. Prehosp Emerg Care. 2025; 29(4):540-545.

View in: PubMed
Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2025 04 01; 8(4):e255340.

View in: PubMed
Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Aug; 120(8):1634-1645.

View in: PubMed
Williams BE, Martin SA, Hoffman KA, Andrus MD, Dellabough-Gormley E, Buchheit BM. "It's within your own power": shared decision-making to support transitions to buprenorphine. Addict Sci Clin Pract. 2025 Mar 07; 20(1):22.

View in: PubMed
Kang AW, Bailey A, Surace A, Stein L, Rohsenow D, Martin RA. Medications for opioid use disorders among incarcerated persons and those in the community supervision setting: exploration of implementation issues with key stakeholders. Addict Sci Clin Pract. 2024 Dec 18; 19(1):95.

View in: PubMed
Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 Sep 12; 19(1):68.

View in: PubMed
Williams AR, Mauro CM, Chiodo L, Huber B, Cruz A, Crystal S, Samples H, Nowels M, Wilson A, Friedmann PD, Remien RH, Olfson M. Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. Drug Alcohol Depend. 2024 Oct 01; 263:112389.

View in: PubMed

People

Explore

Similar Concepts

Top Journals